Plain-English translation of NCT07001800 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new medication, can slow down the buildup of calcium on your aortic valve and help preserve how well your valve works. The study will enroll about 1,276 people with moderate calcific aortic valve stenosis—a condition where calcium deposits gradually build up on one of your heart's valves. Researchers want to see if this medication can help you stay healthier for longer without needing surgery.
Currently, there are limited treatment options to slow down the calcium buildup on the aortic valve once it has started. This trial exists because doctors hope this medication might help preserve your valve function and delay or prevent the need for valve surgery in the future.
You likely qualify if…
You likely don't qualify if…
The study happens in two phases. In the first phase (Part A), about 132 participants will take either the medication or a placebo and have their heart valve calcium deposits monitored. Once Part A is complete, Part B will begin, enrolling about 1,144 participants to test whether the medication slows valve function loss and improves exercise capacity. Throughout the study, you'll have regular heart imaging, blood tests, and possibly exercise testing to track how your valve is doing.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States